ArticleProceedings of the National Academy of Sciences of the United States of America2003

Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling.

Valerie I Brown et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.